Evidence map›Paper›PMID 29301355›Full record

ArticleCells2018

Reagent Tracker Dyes Permit Quality Control for Verifying Plating Accuracy in ELISPOT Tests.

Alexander Lehmann, Zoltan Megyesi, Anna Przybyla, Paul V Lehmann

Open access · goldAbstract read
In one paragraph

Article in Cells, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Unbiased, High-Throughput Identification of T Cell Epitopes by ELISPOT.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Alexander LehmannResearch and Development Department, CTL, Shaker Heights, OH 44122, USA. alexander.lehmann@immunospot.com.
Zoltan MegyesiResearch and Development Department, CTL, Shaker Heights, OH 44122, USA. zoltan.megyesi@immunospot.com.
Anna PrzybylaResearch and Development Department, CTL, Shaker Heights, OH 44122, USA. anna.przybyla@immunospot.com.
Paul V LehmannResearch and Development Department, CTL, Shaker Heights, OH 44122, USA. paul.lehmann@immunospot.com.
Shaker Heights Public Library · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ELISPOT assays enable the detection of the frequency of antigen-specific T cells in the blood by measuring the secretion of cytokines, or combinations of cytokines, in response to antigenic challenges of a defined population of PBMC. As such, these assays are suited to establish the magnitude and quality of T cell immunity in infectious, allergic, autoimmune and transplant settings, as well as for measurements of anti-tumor immunity. The simplicity, robustness, cost-effectiveness and scalability of ELISPOT renders it suitable for regulated immune monitoring. In response to the regulatory requirements of clinical and pre-clinical immune monitoring trials, tamper-proof audit trails have been introduced to all steps of ELISPOT analysis: from capturing the raw images of assay wells and counting of spots, to all subsequent quality control steps involved in count verification. A major shortcoming of ELISPOT and other related cellular assays is presently the lack of audit trails for the wet laboratory part of the assay, in particular, the assurance that no pipetting errors have occurred during the plating of antigens and cells. Here, we introduce a dye-based reagent tracking platform that fills this gap, thereby increasing the transparency and documentation of ELISPOT test results.

Indexed as

antigen screeningaudit trails for ELISPOTCD4 cellsCD8 cellsdeterminant mappingImmunoSpot®regulated ELISPOTRT dyesT cells

Identifiers

PMID29301355
PMCPMC5789276
OpenAlexW2782035487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.